<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2760">
  <stage>Registered</stage>
  <submitdate>6/05/2010</submitdate>
  <approvaldate>6/05/2010</approvaldate>
  <nctid>NCT01120795</nctid>
  <trial_identification>
    <studytitle>Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy</studytitle>
    <scientifictitle>Pegylated Interferon Alfa-2a Plus Ribavirin for Patients With Chronic Hepatitis c Virus on Opioid Pharmacotherapy: Virological and Psychological Outcomes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>HREC 2000.175</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis C</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Pegylated interferon and ribavirin
Treatment: drugs - Pegylated interferon and ribavirin

Experimental: pegylated interferon and ribavirin - Anti hepatitis C agents


Treatment: drugs: Pegylated interferon and ribavirin
Pegylated interferon 180 ug subcutaneous per week Ribavirin 1000-1200 mg /day for genotype 1 and 800 mg /day orally for genotype non 1 Duration: 48 weeks for genotype 1 and 24 weeks for gentoype non 1

Treatment: drugs: Pegylated interferon and ribavirin
Pegylated interferon 180 ug/ week subcutaneously Ribavrin 1000-1200 mg /day for genotype 1 and 800 mg/day orally for genotype 2 and 3 Treatment duration 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sustained virological response</outcome>
      <timepoint>24 weeks post cessation of HCV therapy</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. 18 years of age or older

          2. on opioid substitution therapy (methadone or buprenorphine)

          3. serologic evidence of chronic hepatitis C infection determined by a detectable
             anti-HCV antibody for 6 months or greater with evidence of detectable HCV RNA

          4. elevated ALT on at least two occasions at least one month apart within the past 6
             months, with at least one during the screening period preceding the initiation of
             study drug dosing.

          5. HCV treatment-na√Øve

          6. Liver biopsy findings consistent with the diagnosis of chronic hepatitis C infection
             (unless contraindicated due to a bleeding disorder)

          7. Compensated liver disease (Child-Pugh Grade A clinical classification).

          8. All fertile males and females receiving ribavirin were required to be using two forms
             of effective contraception during treatment and during the 6 months after treatment

          9. Women of child bearing potential were required to have a negative urine or blood
             pregnancy test documented within the 24-hour period prior to the first dose of study
             drug</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Women who were pregnant, breastfeeding or planning a pregnancy

          2. Male partners of women who were pregnant

          3. Patients who had previously received therapy with any systemic anti-neoplastic or
             immunomodulatory treatment (including supraphysiologic doses of steroids and
             radiation) 6 months prior to the first dose of study drug

          4. Recipients of any investigational drug 4 weeks or 5 half lives, whichever was longer,
             prior to the first dose of study drug

          5. A positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, anti-HIV Ab

          6. A history or other evidence of a medical condition associated with chronic liver
             disease other than HCV

          7. Haemoglobin &lt;12 g/dL in women or &lt;13 g/dL in men, a neutrophil count &lt;1500 cells/mm3
             or platelet count &lt;90,000 cells/mm3 at screening and serum creatinine level &gt;1.5 times
             the upper limit of normal at screening.)

          8. A history of a severe seizure disorder or current anticonvulsant use

          9. Patients with a history of immunologically-mediated disease, chronic pulmonary disease
             associated with functional limitation, severe cardiac disease, coronary artery
             disease, cerebrovascular disease, major organ transplantation or other evidence of
             severe illness, malignancy, or any other conditions which would make the patient, in
             the opinion of the investigator, unsuitable for the study

         10. Patients with a history of thyroid disease which is poorly controlled on prescribed
             medications

         11. Evidence of severe retinopathy

         12. Evidence of excessive substance abuse as judged by the investigator

         13. Patients with an increased baseline risk for anaemia (e.g. thalassaemia,
             spherocytosis, history of gastrointestinal bleeding, etc) or for whom anemia would be
             medically problematic.

         14. Patients with a history of severe psychiatric disease (defined as acute phase of
             schizophrenia or bipolar disorder manic, mixed or depressive phase, severe anorexia,
             history of severe multiple episodes of self harm, currently screening as high or
             moderate suicide risk, current major depressive episode or current psychosis of any
             cause at screening)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>55</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Nepean Hospital - Sydney</hospital>
    <hospital>St Vincents Hospital - Sydney</hospital>
    <hospital>Western Hospital - Footscray</hospital>
    <hospital>Royal Melbourne Hospital - Melbourne</hospital>
    <postcode> - Sydney</postcode>
    <postcode>3011 - Footscray</postcode>
    <postcode>3050 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>The University of New South Wales</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>St Vincent's Hospital, Sydney</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Western Hospital, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Monash University</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Hoffmann-La Roche</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to see if treatment of chronic hepatitis C in people who are on
      opiate replacement therapy such as methadone or buprenorphine (including patient who still
      inject drugs) is safe and effective.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01120795</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Joseph J Sasadeusz, MBBS</name>
      <address>Melbourne Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>